The type of vaccine to use in an outbreak is dependent on the serogroup causing the outbreak and the age of those being vaccinated as outlined in At high risk due to underlying medical conditions - refer to In general, a minimum four week interval is recommended between doses of conjugate meningococcal vaccines; however, in an outbreak or to manage a close contact of a case of IMD, the second dose of conjugate meningococcal vaccine may be given as soon as indicated to provide protection to a close contact who is unvaccinated for the implicated serogroup.Individuals at high risk due to underlying medical conditions routinely need two doses of Men-C-ACYWOnly for outbreak control of IMD caused by serogroup B strains that are predicted to be susceptible to the vaccine. HCW are considered as close contacts only if they have had intensive, unprotected contact (without wearing a mask) with infected patients (e.g., intubating, resuscitating or closely examining the oropharynx).
Higher rates of fever have been observed with simultaneous administration of 4CMenB vaccine and routine infant vaccines; therefore, routine prophylactic administration of acetaminophen or separating 4CMenB vaccination from routine vaccination schedule has been proposed for preventing fever in infants and children up to three years of age.Solicited local and systemic reactions have been commonly reported in clinical trials and include injection site tenderness, induration and irritability.Serious adverse events are rare following immunization and, in most cases, data are insufficient to determine a causal association.To ensure the ongoing safety of vaccines in Canada, reporting of AEFIs by vaccine providers and other clinicians is critical, and in some jurisdictions, reporting is mandatory under the law.Vaccine providers are asked to report AEFIs, through For additional information about AEFI reporting, please refer to Meningococcal vaccine is contraindicated in persons with a history of anaphylaxis after previous administration of the vaccine and in persons with proven immediate or anaphylactic hypersensitivity to any component of the vaccine or its container.
Men-C-C is routinely given at 12 months of age if they have not previously been immunized as infants or toddlers. Table 3: Recommended immunization schedule for travellers to destinations where risk of meningococcal transmission is high, not previously immunized with quadrivalent conjugate meningococcal vaccines or serogroup B meningococcal vaccine Age Recommended vaccine(s) Schedule … MenB-fHBP can be given concomitantly with quadrivalent human papillomavirus vaccine; meningococcal serogroup A, C, Y, W conjugate vaccine; and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed. in high risk individuals due to exposure or underlying medical conditions), the use of conjugate and serogroup B meningococcal vaccines in pregnancy and breastfeeding may be considered.
Version: 2.01.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. The bacteria can also live on things the infected person has touched, such as a door handle or other surface. Select one or more newsletters to continue.
polymorphisms in the genes for mannose-binding lectin and tumor necrosis factor); household exposure to an infected person; recent infection with influenza; household crowding; and active and passive smoking. The increased risk of disease for household contacts persists for up to 1 year after disease in the index case and beyond any protection from antibiotic chemoprophylaxis. However, there is no theoretical reason to suspect that adverse events will occur and, in circumstances in which the benefits outweigh the risks (i.e. The booster dose should be administered in the second year of life.Men-C-ACYW-CRM may be given a minimum of 4 weeks apart if accelerated immunization is needed.Serogroup B Meningococcal vaccines are not authorized for use in those 26 years of age and older and Men-C-ACYW vaccines are not authorized for use in those 56 years of age and older; however, based on limited evidence and expert opinion their use is considered appropriate above these authorized ages.Health care providers who see persons newly arrived in Canada should review the immunization status and update immunization for these individuals. Refer to There are no published data regarding the interchangeability of Men-C-C vaccines, but the vaccines have been safely interchanged without a noticeable decrease in efficacy. Outbreaks may be controlled by the use of a conjugate meningococcal vaccine. Since the ACIP meningococcal serogroup B vaccine recommendations state that the same vaccine must be used for all doses in the MenB series, the clinician needs to com-plete a series with one or the other vaccine.
This vaccine contains four common strains of group B meningococcal bacteria.This vaccine helps your body develop immunity to meningitis, but will not treat an active infection you already have.Meningococcal group B vaccine is for use in children and young adults who are 10 to 25 years old.
Higher rates of fever have been observed with simultaneous administration of 4CMenB vaccine and routine infant vaccines; therefore, routine prophylactic administration of acetaminophen or separating 4CMenB vaccination from routine vaccination schedule has been proposed for preventing fever in infants and children up to three years of age.Solicited local and systemic reactions have been commonly reported in clinical trials and include injection site tenderness, induration and irritability.Serious adverse events are rare following immunization and, in most cases, data are insufficient to determine a causal association.To ensure the ongoing safety of vaccines in Canada, reporting of AEFIs by vaccine providers and other clinicians is critical, and in some jurisdictions, reporting is mandatory under the law.Vaccine providers are asked to report AEFIs, through For additional information about AEFI reporting, please refer to Meningococcal vaccine is contraindicated in persons with a history of anaphylaxis after previous administration of the vaccine and in persons with proven immediate or anaphylactic hypersensitivity to any component of the vaccine or its container.
Men-C-C is routinely given at 12 months of age if they have not previously been immunized as infants or toddlers. Table 3: Recommended immunization schedule for travellers to destinations where risk of meningococcal transmission is high, not previously immunized with quadrivalent conjugate meningococcal vaccines or serogroup B meningococcal vaccine Age Recommended vaccine(s) Schedule … MenB-fHBP can be given concomitantly with quadrivalent human papillomavirus vaccine; meningococcal serogroup A, C, Y, W conjugate vaccine; and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed. in high risk individuals due to exposure or underlying medical conditions), the use of conjugate and serogroup B meningococcal vaccines in pregnancy and breastfeeding may be considered.
Version: 2.01.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. The bacteria can also live on things the infected person has touched, such as a door handle or other surface. Select one or more newsletters to continue.
polymorphisms in the genes for mannose-binding lectin and tumor necrosis factor); household exposure to an infected person; recent infection with influenza; household crowding; and active and passive smoking. The increased risk of disease for household contacts persists for up to 1 year after disease in the index case and beyond any protection from antibiotic chemoprophylaxis. However, there is no theoretical reason to suspect that adverse events will occur and, in circumstances in which the benefits outweigh the risks (i.e. The booster dose should be administered in the second year of life.Men-C-ACYW-CRM may be given a minimum of 4 weeks apart if accelerated immunization is needed.Serogroup B Meningococcal vaccines are not authorized for use in those 26 years of age and older and Men-C-ACYW vaccines are not authorized for use in those 56 years of age and older; however, based on limited evidence and expert opinion their use is considered appropriate above these authorized ages.Health care providers who see persons newly arrived in Canada should review the immunization status and update immunization for these individuals. Refer to There are no published data regarding the interchangeability of Men-C-C vaccines, but the vaccines have been safely interchanged without a noticeable decrease in efficacy. Outbreaks may be controlled by the use of a conjugate meningococcal vaccine. Since the ACIP meningococcal serogroup B vaccine recommendations state that the same vaccine must be used for all doses in the MenB series, the clinician needs to com-plete a series with one or the other vaccine.
This vaccine contains four common strains of group B meningococcal bacteria.This vaccine helps your body develop immunity to meningitis, but will not treat an active infection you already have.Meningococcal group B vaccine is for use in children and young adults who are 10 to 25 years old.